One of the misconceptions in breast cancer treatment is that chemotherapy is valued and endocrine therapy is not. Chemotherapy means that a specific concentration of drugs is used to kill a certain percentage of residual cancer cells within a certain period of time. The main side effects of chemotherapy are bone marrow suppression, hair loss, nausea, vomiting and neurotoxicity. Most patients have to endure the toxic side effects caused by chemotherapy, and their quality of life is reduced. Unlike other malignant tumors, the development of breast cancer is closely related to the abnormal estrogen level and metabolism in the body. In fact, endocrine therapy is adapted to almost all stages of ER-positive cases. Due to the mild adverse effects during treatment, endocrine therapy is the best indication for estrogen or progesterone positive patients who need systemic treatment, who are elderly, frail or have other coexisting diseases that cannot tolerate chemotherapy. Endocrine therapy for breast cancer only exerts its therapeutic effect by affecting the hormonal environment; the drugs themselves are not hormones. Three levels of therapy are available: anti-estrogen, pituitary RH-LH analogs and aromatase inhibitors. Anti-estrogen therapy can be divided into three types: surgical debulking, radiotherapy debulking, and pharmacotherapy. The first two mainly reduce the level of estrogen in the blood directly or indirectly by surgical removal of the ovaries or by inhibiting ovarian function through radiotherapy, removal of the adrenal glands and pituitary gland, etc. Surgical depot is more psychologically devastating to women and is an irreversible measure, which is now less commonly used. In contrast, reversible RH-LH analogues are commonly used for Norelide, which can effectively inhibit estrogen synthesis in the ovaries, mainly for pre-menopausal patients, and is more acceptable to many young patients today when quality of life is advocated. As the core drug for endocrine treatment of breast cancer, triamcinolone acetonide is effective in both pre-menopausal and post-menopausal cases with positive receptors. The recent introduction of 3rd generation aromatase inhibitors, including anastrozole, letrozole and exemestane, has challenged the status of TAM as the gold standard. Compared with triamcinolone acetonide, Als is better tolerated in long-term adjuvant therapy and has low side effects. In recent years, a large number of international clinical studies have proved that Als is effective and well tolerated, and can be the first choice of endocrine therapy for early postmenopausal breast cancer and the first-line treatment for advanced postmenopausal breast cancer. Endocrine therapy is a treatment that directly targets the stimulating factors for the development of breast cancer, by inhibiting or reducing the secretion of related hormones and lowering their levels. Endocrine therapy is more targeted and selective, and its toxicity is often milder, but its therapeutic value is huge in suitable patients, which we often overlook in our clinical work. Therefore, doctors and patients should use endocrine therapy with confidence, so that more estrogen receptor-positive patients can be free from chemotherapy toxicity and have a healthy and happy every day.